Abstract
Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have